BEAM240719C35000
- 0.45
- 0.000.00%
Beam Therapeutics Newsroom
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk
Beam Therapeutics (BEAM) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $23 to $78.
Express News | Beam Therapeutics Inc : RBC Cuts Target Price to $27 From $35
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Beam Therapeutics(BEAM.US) Officer Sells US$1.47 Million in Common Stock
$Beam Therapeutics(BEAM.US)$ Officer Evans John M. sold 60,000 shares of common stock on Jun 27, 2024 at an average price of $24.5026 for a total value of $1.47 million.Source: Announcement What is st
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing
John M. Evans, Director, CEO, on June 27, 2024, sold 60,000 shares in Beam Therapeutics (BEAM) for $1,470,156. Following the Form 4 filing with the SEC, Evans has control over a total of 1,101,343 sha
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 1.47 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 27, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Jun 27, with a total market value of approximately $1.47 million.
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Wells Fargo analyst Yanan Zhu maintains $Beam Therapeutics(BEAM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.9% and a total average return of 12.6% over the
Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitrypsin Deficiency, Currently In Phase 1/2 Trial
Beam Therapeutics Announced The First Patient Was Treated With BEAM-302, An Investigational In Vivo Base Editing Medicine Designed To Precisely Correct The Underlying Cause Of Severe Alpha-1 Antitryps
Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)
CCORF Initiates Beam Therapeutics(BEAM.US) With Hold Rating, Announces Target Price $42
CCORF analyst Mary Kate initiates coverage on $Beam Therapeutics(BEAM.US)$ with a hold rating, and sets the target price at $42.According to TipRanks data, the analyst has a success rate of 0.0% and a
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized,
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella,
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays